Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Temporal Immune Profiling Reveals How Sepsis States Change Over Time

By LabMedica International staff writers
Posted on 31 Aug 2026

Sepsis is a life-threatening condition in which the immune response to infection becomes dysregulated, leading to rapid organ failure and death. More...

Although antimicrobials and organ support remain standard care, many patients continue to deteriorate, and immune-targeted therapies have not reliably improved outcomes. A major challenge is that patients’ immune status can shift during critical illness, making it difficult to know when host-directed treatments are most likely to help. To address this timing gap, researchers have now mapped how immune states change over time in adult sepsis to inform the selection and timing of future therapies.

King’s College London has delineated three time-varying sepsis temporal immune states (STImS) that span the course from intensive care admission to recovery. The work, published in Immunity on August 28, 2026, builds a structured, time-based “immune profile” to capture the architecture of the host response during illness. The study proposes that aligning treatment strategies to these evolving immune states could improve how clinicians target the misfiring immune system.

Investigators analyzed blood from critically ill adults with sepsis treated at Guy’s and St Thomas’ NHS Foundation Trust, sampling at four points between admission and discharge from critical care. They assembled multiple layers of immune-response information from each sample, including immune cell data, gene expression, and changing protein expression. Using machine learning approaches, they integrated these layers to generate a comprehensive patient immune profile across time.

The resulting analyses revealed three distinct temporal immune states between admission and recovery, each marked by different immune-cell activities and response programs. Crucially, these immune states did not align with conventional clinical staging; for example, the “early” immune state (STImS1) was not the same as the early clinical stage often assigned on the day of diagnosis. The findings suggest that identifying a patient’s current immune state could help determine which immune-directed therapies to use and when to use them.

The study involved collaborators at University College London. The authors note that the next priority is to define what drives the transition from initial infection to sepsis, with the aim of identifying targets to reduce progression or severity.

“The main aim of this work was to build a profile of sepsis immune responses over time. When people are admitted to a hospital with sepsis, they are usually classed as having ‘early’ sepsis—but our findings show that this isn’t necessarily the case—their immune system may already be at later stages of the immune response. Knowing exactly what is happening to a patient’s immune system during sepsis could identify which treatments are likely to work best,” said Matthew Fish, former Ph.D. student at King’s College London and lead author of the paper.

“This research shows the importance of looking at the changing architecture of the immune system in sepsis over time, rather than just taking a snapshot view. We need to find better ways to treat the misfiring immune system. Only by understanding the intricacies of the immune system in all its component parts—by integrating and dynamically mapping cell and molecular immunobiology to determine why the very system designed to protect us from infections is misfiring in sepsis—can we begin to improve outcomes for patients by treating the misfiring immune system,” said Manu Shankar-Hari, professor of critical care medicine at King’s College London, honorary consultant at Guy’s and St Thomas’ NHS Foundation Trust and senior author of the paper.

Related Links
King’s College London


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.